Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
The price of Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) closed at $40.02 in the last session, down -2.08% from day before closing price of $40.87. In other words, the price has decreased by -$2.08 from its previous closing price. On the day, 1.13 million shares were traded.
Ratios:
We take a closer look at RARE’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 2.24 and its Current Ratio is at 2.37. In the meantime, Its Debt-to-Equity ratio is 3.56 whereas as Long-Term Debt/Eq ratio is at 3.33.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on June 06, 2024, Upgraded its rating to Buy and sets its target price to $67 from $56 previously.
On April 22, 2024, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $77.
On December 08, 2023, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $72.Wells Fargo initiated its Overweight rating on December 08, 2023, with a $72 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 03 ’25 when Kassberg Thomas Richard sold 6,028 shares for $42.10 per share. The transaction valued at 253,779 led to the insider holds 265,238 shares of the business.
Parschauer Karah Herdman sold 12,846 shares of RARE for $540,817 on Mar 03 ’25. The EVP and Chief Legal Officer now owns 75,287 shares after completing the transaction at $42.10 per share. On Mar 03 ’25, another insider, Crombez Eric, who serves as the EVP and Chief Medical Officer of the company, sold 8,945 shares for $42.10 each. As a result, the insider received 376,584 and left with 71,922 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 6.61 while its Price-to-Book (P/B) ratio in mrq is 14.49.
Stock Price History:
Over the past 52 weeks, RARE has reached a high of $60.37, while it has fallen to a 52-week low of $37.02. The 50-Day Moving Average of the stock is -6.54%, while the 200-Day Moving Average is calculated to be -15.29%.
Shares Statistics:
A total of 92.41M shares are outstanding, with a floating share count of 86.48M. Insiders hold about 6.51% of the company’s shares, while institutions hold 95.14% stake in the company.
